Esperion Therapeutics Total Revenue

As of the most recent data (March 2026), ESPR shows a total revenue of $420M. That compares with $260M in the prior-year period — up 61.1% year over year. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ESPR's total revenue is now $420M (was $260M) — a 61.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Esperion Therapeutics is outperforming or lagging.

The Healthcare sector average total revenue is about $110B. Esperion Therapeutics is at $420M, which is lower that average. That is roughly 99.6% below the sector mean. Use the comparison chart on this page to see how ESPR stacks up against individual peers as well.

Tracking ESPR's total revenue over time shows whether Esperion Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $420M That compares with $260M in the prior-year period — up 61.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total revenue page, Stockcircle has Esperion Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $420M) with ownership activity and broader fundamentals.